IGCS 2022

IGCS 2022

Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer 2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
Optimal management of recurrent low grade endometrial cancer 4:15
Optimal management of recurrent low grade endometrial cancer
Mansoor Mirza • 29 Sep 2022
Highlights from IGCS 2022 0:37
Highlights from IGCS 2022
Elaine Leung • 30 Sep 2022
Research allocation and international collaboration 0:57
Research allocation and international collaboration
Elaine Leung • 30 Sep 2022
Learnings from COVID-19 on the surgical management of gynecological cancer patients 0:58
Learnings from COVID-19 on the surgical management of gynecological cancer patients
Elaine Leung • 30 Sep 2022
Outcomes of gynecological cancer surgery during the COVID-19 pandemic 1:59
Outcomes of gynecological cancer surgery during the COVID-19 pandemic
Elaine Leung • 30 Sep 2022
Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary 3:26
Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary
Lilian T. Gien • 3 Oct 2022
Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovary 2:10
Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovary
Lilian T. Gien • 3 Oct 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals